Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip Krag Knop

Showing results (11-20 of 98) with videos related to

Pageof 10
Sort By:
Ugeskrift for Laeger|March 2, 2019
[Biomarkers of cardiovascular disease in patients with Type 2 diabetes]Sara Kull Krogh, Andreas Andersen, Filip Krag Knop, et al.
Ugeskrift for Laeger|April 2, 2019
[Glucagon-like peptide 1 receptor agonists for the treatment of Type 2 diabetes]Andreas Andersen, Alexander Sidelmann Christensen, Filip Krag Knop, et al.
Endocrinology, Diabetes & Metabolism Case Reports|December 26, 2022
Incidental finding of non-alcoholic steatohepatitis-cirrhosisTherese Adrian, Mads Hornum, Filip Krag Knop, et al.
Endocrine Connections|June 17, 2021
How glucagon-like peptide 1 receptor agonists workChristine Rode Andreasen, Andreas Andersen, Filip Krag Knop, et al.
Diabetes, Obesity & Metabolism|September 14, 2021
Understanding the place for GLP-1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selectionChristine Rode Andreasen, Andreas Andersen, Filip Krag Knop, et al.
Expert Opinion on Drug Discovery|October 20, 2018
Preclinical discovery and development of colesevelam for the treatment of type 2 diabetesHenriette Holst Nerild, Mikkel Bring Christensen, Filip Krag Knop, et al.
Ugeskrift for Laeger|June 2, 2023
Martin Lund Kårhus, Anne-Marie Ellegaard, Iben Rix, et al.
Expert Opinion on Pharmacotherapy|February 29, 2020
Clinical pharmacology of imeglimin for the treatment of type 2 diabetesKarl Sebastian Johansson, Andreas Brønden, Filip Krag Knop, et al.
Ugeskrift for Laeger|March 7, 2013
[Psoriasis is associated with type 2 diabetes]Mette Gyldenløve, Filip Krag Knop, Tina Vilsbøll, et al.
Diabetes, Obesity & Metabolism|August 5, 2021
Exendin(9-39)NH<sub>2</sub> : Recommendations for clinical use based on a systematic literature reviewLaerke Smidt Gasbjerg, Emilie Johanning Bari, Mikkel Christensen, et al.
Pageof 10

Showing results (11-20 of 98) with videos related to

Sort By:
Pageof 10
Ugeskrift for Laeger|March 2, 2019
[Biomarkers of cardiovascular disease in patients with Type 2 diabetes]Sara Kull Krogh, Andreas Andersen, Filip Krag Knop, et al.
Ugeskrift for Laeger|April 2, 2019
[Glucagon-like peptide 1 receptor agonists for the treatment of Type 2 diabetes]Andreas Andersen, Alexander Sidelmann Christensen, Filip Krag Knop, et al.
Endocrinology, Diabetes & Metabolism Case Reports|December 26, 2022
Incidental finding of non-alcoholic steatohepatitis-cirrhosisTherese Adrian, Mads Hornum, Filip Krag Knop, et al.
Endocrine Connections|June 17, 2021
How glucagon-like peptide 1 receptor agonists workChristine Rode Andreasen, Andreas Andersen, Filip Krag Knop, et al.
Diabetes, Obesity & Metabolism|September 14, 2021
Understanding the place for GLP-1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selectionChristine Rode Andreasen, Andreas Andersen, Filip Krag Knop, et al.
Expert Opinion on Drug Discovery|October 20, 2018
Preclinical discovery and development of colesevelam for the treatment of type 2 diabetesHenriette Holst Nerild, Mikkel Bring Christensen, Filip Krag Knop, et al.
Ugeskrift for Laeger|June 2, 2023
Martin Lund Kårhus, Anne-Marie Ellegaard, Iben Rix, et al.
Expert Opinion on Pharmacotherapy|February 29, 2020
Clinical pharmacology of imeglimin for the treatment of type 2 diabetesKarl Sebastian Johansson, Andreas Brønden, Filip Krag Knop, et al.
Ugeskrift for Laeger|March 7, 2013
[Psoriasis is associated with type 2 diabetes]Mette Gyldenløve, Filip Krag Knop, Tina Vilsbøll, et al.
Diabetes, Obesity & Metabolism|August 5, 2021
Exendin(9-39)NH<sub>2</sub> : Recommendations for clinical use based on a systematic literature reviewLaerke Smidt Gasbjerg, Emilie Johanning Bari, Mikkel Christensen, et al.
Pageof 10